Glaukos Corp
Fechado
SetorSaúde
129.93 1.93
Visão Geral
Variação de preço das ações
24h
Mín
124.68
Máximo
131.02
Rendimento | 114M -20M |
|---|---|
Vendas | 7.5M 151M |
EPS | -0.18 |
Margem de lucro | -13.139 |
Funcionários | 1,094 |
EBITDA | 124M -5.3M |
Recomendações | Compra Forte |
|---|---|
Previsão para 12 meses | +23.5% upside |
Próximos Ganhos | 29 de jul. de 2026 |
|---|
Capitalização de Mercado | 487M 7.6B |
|---|---|
Abertura anterior | 128 |
Fecho anterior | 129.93 |
Sentimento de Notícias
By Acuity
42%
58%
138 / 342 Ranking em Healthcare
Glaukos Corp Gráfico
O desempenho passado não é um indicador confiável de resultados futuros.
Sobre Glaukos Corp
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.